Clinical Trials
12 trialsNCT07410117 2026-05-27
ROXI-CAT-I
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT05171075 2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT07493304 2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT06861088 2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3 Recruiting
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT03240120 2019-04-17
A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
The University of Hong Kong
Phase 3 Unknown
NCT02073682 2019-03-06
Cancer Venous Thromboembolism (VTE)
Daiichi Sankyo
Phase 3 Completed
NCT00876915 2015-11-24
PHACS
University of Rochester
Phase 3 Terminated
NCT00219973 2010-04-28
CANBESURE STUDY (Cancer, Bemiparin and Surgery Evaluation)
Rovi Pharmaceuticals Laboratories
Phase 3 Completed
NCT00135876 2007-04-27
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Ontario Clinical Oncology Group (OCOG)
Phase 3 Completed